Opus Point Partners Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Opus Point Partners Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-25,000	Closed	-$980K	–	71
2017 Q1	$980K	Hold	25,000	–	–	0.73%	36
2016 Q4	$561K	Hold	25,000	–	–	0.45%	37
2016 Q3	$568K	Buy	+25,000	New	+$587K	0.32%	37

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Opus Point Partners Management's PTLA Position: Q2 2017 in Review

Opus Point Partners Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2017, closing a stake of 25,000 shares — an estimated $980K sold.

Opus Point Partners Management first reported a position in PTLA in Q3 2016 and held it in 3 quarters. The position peaked at $980K in Q1 2017. 206 funds tracked by Wall St. Rank hold PTLA as of Q2 2017.

Opus Point Partners Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Opus Point Partners Management sold 25,000 Portola Pharmaceuticals, Inc. shares in Q2 2017, an estimated $980K.
Opus Point Partners Management first reported a position in Portola Pharmaceuticals, Inc. in Q3 2016 and held it in 3 quarters.
Opus Point Partners Management's Portola Pharmaceuticals, Inc. position peaked at $980K in Q1 2017.
206 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2017.

Based on Opus Point Partners Management's 13F filing for Q2 2017, filed 14 Aug 2017.